Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | BMP1 | P13497 | 7/20 | 0.38 |
| ▸ | VIPR2 | P41587 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.36 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5633526 | 0.88 | BACE1 (0.43) | BACE1MMP2MMP13ALDH1A1HPGD | |
| SCHEMBL5634518 | 0.88 | BACE1 (0.42) | BACE1MMP2MMP13ALDH1A1HPGD | |
| SCHEMBL7243370 | 0.87 | BACE1 (0.42) | BACE1MMP2MMP13ALDH1A1HPGD | |
| SCHEMBL5633798 | 0.87 | BACE1 (0.42) | BACE1MMP2MMP13BMP1 | |
| SCHEMBL5634147 | 0.86 | BACE1 (0.41) | BACE1MMP2MMP13BMP1KEAP1 | |
| SCHEMBL6261536 | 0.86 | BMP1 (0.45) | BACE1ALDH1A1HTTBMP1LMNA | |
| SCHEMBL5632828 | 0.83 | BMP1 (0.43) | BACE1MMP2MMP13ALDH1A1HTT | |
| SCHEMBL6260340 | 0.82 | BMP1 (0.48) | BACE1MMP13ALDH1A1HTTBMP1 | |
| SCHEMBL6260176 | 0.81 | BMP1 (0.39) | BACE1MMP2MMP13ALDH1A1HTT | |
| SCHEMBL8183791 | 0.81 | ALDH1A1 (0.46) | MMP2MMP13ALDH1A1HPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0804428-B1 | BIS-SULFONAMIDE HYDROXYETHYLAMINO RETROVIRAL PROTEASE INHIBITORS | SEARLE LLC (US) | 2007-12-26 | — | — | EP | claimed |
| EP-1586558-A2 | Bis-sulfonamide hydroxyethylamino retroviral protease inhinitors | G.D. Searle LLC. (US) | 2005-10-19 | — | — | EP | claimed |
| US-20040063771-A1 | Bis-sulfonamide hydroxyethyl-amino retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2004-04-01 | — | — | US | claimed |
| US-20030013751-A1 | Bis-sulfonamide hydroxyethyl-amino retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2003-01-16 | — | — | US | claimed |
| US-6384036-B1 | Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors | G.D. SEARLE & CO. | 2002-05-07 | — | — | US | claimed |
| WO-1996022287-A1 | BIS-SULFONAMIDE HYDROXYETHYLAMINO RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-07-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013751-A1 | Bis-sulfonamide hydroxyethyl-amino retroviral protease inhibitors | DNPEP, PRSS1, PREP | BACE1 54/4885MMP2 271/4885MMP13 512/4885 |
| US-20040063771-A1 | Bis-sulfonamide hydroxyethyl-amino retroviral protease inhibitors | DNPEP, PRSS1, PREP | BACE1 54/4885MMP2 271/4885MMP13 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.